Yayın:
Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML) - Outcome of discontinuation of imatinib therapy after achieving a molecular remission

Basit Görünüm
dc.contributor.buuauthorAli, Rıdvan
dc.contributor.buuauthorÖzkalemkaş, Fahir
dc.contributor.buuauthorÖzçelik, Tülay
dc.contributor.buuauthorÖzkocaman, Vildan
dc.contributor.buuauthorOzan, Ülkü
dc.contributor.buuauthorKimya, Yalçın
dc.contributor.buuauthorKöksal, Nilgün
dc.contributor.buuauthorGülten, Tuna
dc.contributor.buuauthorYakut, Tahsin
dc.contributor.buuauthorTunalı, Ahmet
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentÇocuk Sağlığı ve Hastalıkları Ana Bilim Dalı
dc.contributor.departmentKadın Hastalıkları ve Doğum Ana Bilim Dalı
dc.contributor.departmentTıbbi Genetik Ana Bilim Dalı
dc.contributor.departmentHematoloji Ana Bilim Dalı
dc.contributor.departmentİç Hastalıkları Ana Bilim Dalı
dc.contributor.researcheridAAH-1854-2021
dc.contributor.researcheridAAG-8495-2021
dc.date.accessioned2021-07-06T10:17:39Z
dc.date.available2021-07-06T10:17:39Z
dc.date.issued2005-08
dc.description.abstractBecause of the teratogenicity data in rats, it is recommended that women treated with imatinib should be aware of the potential teratogenicity of imatimb and effective contraception should be used during imatinib therapy to prevent pregnancy. We describe successful pregnancy and delivery, without any congenital anomaly, in a patient with CML under treatment of imatinib. The fetus had been exposed to imatinib for 8 weeks. The patient remained off treatment during gestation and cytogenetic relapse of CML (5 months after discontinuation of imatinib therapy) developed at seventh month of gestation. (c) 2005 Elsevier Ltd. All rights reserved.
dc.identifier.citationAli, R. vd. (2005). "Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML) - Outcome of discontinuation of imatinib therapy after achieving a molecular remission", Leukemia Research, 29(8), 971-973.
dc.identifier.doi10.1016/j.leukres.2005.01.009
dc.identifier.endpage973
dc.identifier.issn0145-2126
dc.identifier.issue8
dc.identifier.pubmed15978950
dc.identifier.scopus2-s2.0-20544435207
dc.identifier.startpage971
dc.identifier.urihttps://doi.org/10.1016/j.leukres.2005.01.009
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0145212605000536
dc.identifier.urihttp://hdl.handle.net/11452/21125
dc.identifier.volume29
dc.identifier.wos000230369800015
dc.indexed.scopusScopus
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherPergamon-Elsevier Science
dc.relation.journalLeukemia Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectChronic myelogenous leukemia
dc.subjectPregnancy
dc.subjectImatinib
dc.subjectManagement
dc.subjectOncology
dc.subjectHematology
dc.subject.wosOncology
dc.subject.wosHematology
dc.titlePregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML) - Outcome of discontinuation of imatinib therapy after achieving a molecular remission
dc.typeArticle
dc.wos.quartileQ2
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/İç Hastalıkları Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Hematoloji Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Kadın Hastalıkları ve Doğum Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Tıbbi Genetik Ana Bilim Dalı
local.indexed.atPubMed
local.indexed.atScopus

Dosyalar

Lisanslı seri

Şimdi gösteriliyor 1 - 1 / 1
Placeholder
Ad:
license.txt
Boyut:
1.71 KB
Format:
Item-specific license agreed upon to submission
Açıklama
İndir

Koleksiyonlar

İndeksli Yayınlar / Indexed Publications